NEW YORK - Immunocore ayaa sheegay Isniintii inay iibin doonto 3,733,333 saamiyada maalgashiga maalgashiga gaarka ah (PIPE) kaas oo la filayo inuu kor u qaado $ 140 million.
Sida ku cad heshiiska, Immunocore waxay iibin doontaa saamigeeda guud iyo saamiyada aan codka ahayn ee $ 37.50. Maal-gashadayaasha shirkadda ee hadda jira ee ka qaybqaata maalgelinta waxaa ka mid ah RTW Investments, Rock Springs Capital iyo General Atlantic.Heshiiska PIPE ayaa la filayaa inuu dhammaado Luulyo 20.
Shirkaddu waxay u isticmaali doontaa dakhliga si ay u maalgeliso musharrixiinta dhuunta cudurrada faafa, oo ay ku jiraan horumarinta musharaxeeda kansarka oncology, Kimmtrak (tebentafusp-tebn), si loogu daweeyo HLA-A*02: 01 maqaarka togan iyo uveal melanoma. Maalgelinta, oo ay weheliso dakhliga ka soo gala Kimmtrak, ayaa la filayaa inay maalgeliso Immunocore's hawlgallada 2025.
Sannadkan, Kimmtrak ayaa loo oggolaaday in loo isticmaalo bukaannada qaba HLA-A * 02: 01 togan oo aan la soo celin karin ama melanoma uveal melanoma ee US, Europe iyo UK, iyo wadamada kale.
Immunocore ayaa sidoo kale horumarinaysa afar musharax oo kale oo oncology ah, oo ay ku jiraan laba daawo oo dheeraad ah oo T-cell ah oo ku jira marxaladda I / II ee tijaabooyinka burooyinka adag ee horumarsan. Mid ka mid ah daawooyinka ayaa loo sameeyay HLA-A * 02: 01-positive iyo MAGE-A4-positive, iyo kuwa kale ee bartilmaameedka HLA-A * 02: 01 iyo PRAME- musharaxiinta horumarinta ayaa sidoo kale leh laba buro oo aan la garanayn.
Siyaasadda Qarsoodiga